Antibacterial efficacy in total safety

  • Description
  • Benefits
  • Indications
  • In Practice
  • FAQs
  • Evidence
  Download product information

Lipido-colloid contact layer impregnated with silver sulphadiazine

Promoting healing and preventing infection:

 

Pain-free and atraumatic dressing removal

A major benefit of TLC healing matrix (Technology Lipido-Colloid) is the non-adherence of the dressing which allows trauma-free removal from the newly-formed tissue with no pain for the patient.

Composition

UrgoTul s.Ag/SSD is an antibacterial, flexible contact layer with TLC-s.Ag, comprised of:

  • A conformable polyester mesh impregnated with fatty substances, hydrocolloid, and silver sulphadiazine.

 

Mode of action

When in contact with wound exudate, the TLC-s.Ag of UrgoTul s.Ag/SSD gels and creates a moist environment, promoting healing. This ensures non-adherence and pain-free dressing changes. UrgoTul s.Ag/SSD acts as a reservoir capable of continuously releasing two anti-microbial agents, silver ions and sulphadiazine, which have a purely topical action.


This website is an international website. Some products or sizes can therefore be unavailable in some countries. For more information, please contact us.

Benefits for the wound

  • Broad spectrum antibacterial efficacy, including MRSA

 

  • Moist wound healing
  • No adherence to the wound (no damage to newly formed tissue)
  • Protection of surrounding skin

benefits-for-professionnalBenefits for health professionals

  • Easy to apply
  • Easy to remove with pain-free dressing change
  • Can be used in cavity wounds
  • Can be used under compression
  • Clinically proven

benefits-for-patientBenefits for patients

  • No adherence to the wound: pain-free dressing change
  • Well tolerated
  • Very conformable to fit different wound shapes

UrgoTul s.Ag/SSD is indicated in the treatment of wounds with local signs of infection: chronic wounds (pressure ulcers and leg ulcers, diabetic foot ulcers, etc) and acute wounds (partial thickness burns, dermabrasions, traumatic wounds, etc).

Due to the non-adhesive nature of the dressing, UrgoTul s.Ag/SSD is recommended for the treatment of wounds in which the skin around the lesion is weakened.

Contraindications

  • Known sensitisation to sulphonamides and other ingredients.
  • Use in patients with renal or hepatic impairment, pregnant or breast-feeding women, newborn and premature babies is contraindicated in the absence of any specific clinical data.
  • Do not use on patients undergoing Magnetic Resonance Imaging (MRI) examination

Side-effects

The silver sulphadiazine can give rise to:

  • Erythema, contact eczema and rare cases of argyria
  • Photosensitivity
  • Leucopenia which are sometimes severe and which usually arise during the first days of treatment.

Passage of sulphadiazine into the systemic blood stream exposes patients to a risk of systemic sulphonamide complications: haematological, renal, intestinal and skin.

Interactions with other medicines and other forms of interaction

  • Specific problems related to an INR (International Normalized Ratio) imbalance. A number of cases of increased activity of oral anticoagulants have been reported in patients taking antibiotics. A marked infectious or inflammatory context, along with the age and general condition of the patient, seem to be risk factors. Under these circumstances, it would appear to be difficult to distinguish between the role of the infectious disease and its treatment in the development of an INR imbalance. However, certain antibiotic classes are more frequently involved: in particular, these include fluoroquinolones, macrolides and cyclins, cotrimoxazole and certain cephalosporins.
  • Increase in the effects and haematological toxicity of methotrexate due to displacement of its plasma protein binding by certain sulphonamides. Assay of methotrexate concentrations. Adjustment of dosage if necessary during the combination and after its discontinuation.

Instructions for use

  • Clean the wound using saline solution only.
  • If an antiseptic is first used, rinse the wound thoroughly with saline solution before applying UrgoTul s.Ag/SSD.
  • UrgoTul s.Ag/SSD can be cut using sterile scissors to fit the dressing size to the wound if necessary.
  • Using the tabs, remove the protective film.
  • Apply UrgoTul s.Ag/SSD to the wound.
  • Cover UrgoTul s.Ag/SSD with a secondary dressing suitable for the location and level of wound exudate.
  • Secure the dressing in place with a suitable bandage, adhesive tape, or an elasticated tubular bandage. Apply a compression bandage when prescribed.
  • UrgoTul s.Ag/SSD should be changed every 24 to 48 hours depending on the level of exudate and the clinical condition of the wound.
  • After one month of treatment, medical staff should reassess the need to continue treatment.

Precautions for use

  • As UrgoTul s.Ag/SSD can adhere to surgical gloves (latex), it is recommended that gloves should be moistened with normal saline to facilitate handling of the dressing.
  • Treatment with Urgotul S.Ag / S.S.D should be carried out under medical supervision.
  • Concomitant use with other local treatments is not recommended.
  • Avoid contact with electrodes or conductive gels during electronic measurements, e.g. EEG and ECG.
  • When the dressing is used over a large surface area which has been injured and/or for a prolonged treatment, on broken skin or an open wound or on mucous membranes, it is not possible to exclude the risk of a systemic effect linked to the silver sulphadiazine (risk of general haematological, renal, intestinal and skin complications).
  • Clinicians / Healthcare Professionals should be aware that there are very limited data on prolonged and repeated use of silver containing dressings, particularly in children and neonates.
  • Discard any unused parts of the dressing.
  • Check that the sterility protector is intact before use.
  • Single-use, individual and sterile dressing: re-using a single-use product may lead to risks of infection.
  • Do not re-sterilise the dressing.

Sizes availableURGOTUL SSD_3D

  • 10 x 12 cm
  • 11 x 11 cm
  • 15 x 20 cm
  • 16 x 21 cm

 


This website is an international website. Some products or sizes can therefore be unavailable in some countries. For more information, please contact us.

Product

What is UrgoTul s.Ag/SSD?

UrgoTul s.Ag/SSD is an antibacterial, flexible contact layer with TLC-s.Ag, comprised of a conformable polyester mesh impregnated with fatty substances, hydrocolloid, and silver sulphadiazine.

How does UrgoTul s.Ag/SSD work?

When in contact with wound exudate, the TLC-s.Ag of UrgoTul s.Ag/SSD gels and creates a moist environment, promoting healing. This ensures non-adherence and pain-free dressing changes. UrgoTul s.Ag/SSD acts as a reservoir capable of continuously releasing two anti-microbial agents, silver ions and sulphadiazine, which have a purely topical action.

Is silver released into the wound bed to kill bacteria or are bacteria killed in contact with the dressing?

TLC-s.Ag contains silver sulphadiazine, whose antibacterial effect is only activated when in contact with wound exudate.

Ag+ ions and sulphadiazine stay in the lipido-colloid gel and are not released in the wound bed.

Does silver go into the blood stream?

TLC-s.Ag contains silver sulphadiazine, whose antibacterial effect is only activated when in contact with wound exudate.

Ag+ ions and sulphadiazine stay in the lipido-colloid gel, their antibacterial activity remains on the wound surface, and is not released in the wound bed, even less so at a systemic level.

The amount of silver in TLC-s.Ag products is low, are they as effective as other silver dressings?
Do I need to change those more often?

In TLC-s.Ag dressings, the Ag+ ions and sulphadiazine have a bactericidal effect with an amount of silver that is enough to be effective on the most resistant pathogens, for up to 7 days (in vitro).

Other dressings may require more silver to be effective as their mechanism of action is different. They quickly release silver and need to have a higher silver amount to be effective over time. This may represent a risk of reduced effectiveness.

Against which pathogens are the TLC-s.Ag dressings effective?

Ag ions and sulphadiazine are effective against a wide range of different pathogens. Tests have even been carried out on resistant pathogens: MRSA, Escherichia coli, proving the efficacy of TLC-s.Ag.
TLC-s.Ag has also demonstrated its antibacterial activity in vitro on 117 hospital strains.

Indications

When should I use UrgoTul s.Ag/SSD?

UrgoTul s.Ag/SSD is indicated for non to low exuding wounds with signs of local infection.

Can I use UrgoTul s.Ag/SSD during the desloughing stage?

Yes, however, UrgoClean is the recommended treatment option for desloughing.

Can I use UrgoTul s.Ag/SSD with a gel?

Yes, it can be combined with a hydrogel.

What are the contraindications of UrgoTul s.Ag/SSD?

UrgoTul s.Ag/SSD should not be used where there is a known sensitivity to sulphonamides and other ingredients.
Do not use on patients undergoing Magnetic Resonance Imaging (MRI) examination.
Use in patients with renal or hepatic impairment, pregnant or breast-feeding women, newborn and premature babies is contraindicated in the absence of any specific clinical data.

Is there any adverse event related to the TLC-s.Ag products?

The silver sulphadiazine can give rise to:

  • Erythema, contact eczema and rare cases of argyria
  • Photosensitivity
  • Leucopenia which are sometimes severe and which usually arise during the first days of treatment.

Passage of sulphadiazine into the systemic blood stream exposes patients to a risk of systemic sulphonamide complications: haematological, renal, intestinal and skin.

However, TLC-s.Ag contains silver sulphadiazine, whose antibacterial effect is only activated when in contact with wound exudate.
Ag+ ions and sulphadiazine stay in the lipido-colloid gel and are not released in the wound bed.

Can I use TLC-s.Ag products in children?

No clinical studies have been carried out. However, TLC-s.Ag has been widely used for the treatment of traumatic wounds and burns in children from the age of one.

Use

UrgoTul s.Ag/SSD can adhere to gloves. How should I avoid this?

It is recommended to moisten the gloves with normal saline and to use the protective wings to facilitate application.

Can I use UrgoTul s.Ag/SSD in combination with another dressing (such as UrgoClean)?

Yes.

Can I use UrgoTul s.Ag/SSD under compression?

Yes.

cutting-dressing-guide

Cutting Guide

Can I cut UrgoTul s.Ag/SSD?

Yes.

How can I secure UrgoTul s.Ag/SSD?

Cover UrgoTul s.Ag/SSD with a secondary dressing suitable for the location and level of wound exudate. Secure the dressing in place with a suitable bandage, adhesive tape, or apply a compression bandage when prescribed.

How long should I keep the dressing in place?

A maximum of four weeks use is recommended due to the good efficacy of TLC-s.Ag on most pathogens.
Dressing should be renewed every 24 to 48 hours, depending on the wound being treated and its progress.

Can I keep the contact layer in place and change only the secondary dressing?

The contact layer may remain in contact with the wound for 24 to 48 hours. If necessary, the secondary dressing can be changed more frequently to manage exudate.

When should I stop using silver sulphadiazine dressings and switch back to a neutral dressing?

A maximum of four weeks use is recommended due to the good efficacy of TLC-s.Ag on most pathogens.
If the wound evolves well before the end of the 4 weeks treatment, you can switch to a neutral dressing.

Evidence

What evidence do you have on TLC-s.Ag?

In vitro data and clinical cases have been carried out; as well as a clinical study on the efficacy and tolerance of Urgotul S.Ag/SSD in the treatment of second degree burns

JWC-134-Carsin-H-4pp_web Urgo_Review_resize_A4_web  
A silver sulphadiazine-impregnated lipidocolloid wound dressing to treat second-degree burns Supporting evidence-based practice: a clinical review of TLC technology

 

Download Download  
Last update : November 23, 2017